Cosmos Pharmaceuticals Inc.’s Post

In what could be termed as a cautious year, there was still plenty of financing round activity in the life sciences industry. Based on Biotechgate data, these are the top 10 rounds sorted by the amount raised. Notably, private equity rounds have not made the cut for the list. Biotechgate Venture Valuation AG #dealmaking #licensing #investments #biopharma https://lnkd.in/gBAywSCT

AAX Biotech Secures Funding to Drive Technology Development and Expansion 🚀 We are excited to announce that AAX Biotech AB has successfully raised 7 MSEK in a funding round backed by both new and existing investors. The capital will be used to support our ongoing growth and innovation efforts, strengthening our internal capabilities and expanding our project portfolio. The funding round included a rights issue offered to current shareholders, alongside a directed share issue aimed at new investors such as Life Science Invest (LSI Epsilon). Several existing shareholders, including Karolinska Institutet Holding, Northislet, Hjalmar Didrikson through HJKK Didrikson AB and Phase2Phase Biopharma Ventures, additionally chose to increase their stake in AAX Biotech. With these resources, we are positioned to deliver innovative solutions that address some of the most critical medical challenges. Full story: https://lnkd.in/dcSBZ5Mm #AAX #Biotech #AntibodyTherapeutics #NextGenTherapeutics #DrugDevelopment

News on the liquidation of Pear Therapeutics (shared without my opinion...best to read my short summary yourself) PursueCare makes headlines with its latest acquisition of assets from Pear Therapeutics, including the renowned reSET, reSET-O, and reSET-A, showcasing its commitment to transformative healthcare solutions. This move follows an announcement from May of this year when Harvest Bio's offered to acquire ISF licenses, patents, and a range of assets related to various healthcare projects from Pear Therapeutics, including reSET and reSET-O. Harvest Bio was discovered to be financially backed by T.Rx Capital Fund, which lists Michael Langer, a former long-term employee of Pear Therapeutics, as its principle. PursueCare's recent Series B funding of $20 million, spearheaded again T.Rx Capital and also includes Yamaha Motor Ventures. These strategic moves signal a dynamic phase for PursueCare, propelling its position as a key player in advancing digital health solutions. Stay tuned for more updates on their transformative journey! #DigitalHealth #HealthcareInnovation #FundingRound #acquisition

Spartan Capital Securities, LLC Serves as Selling Group Member in Alpha Cognition, Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing   We are proud to announce that Spartan Capital Securities LLC participated as a selling group member in Alpha Cognition Inc.'s successful $4.454 million bridge financing. This financing, comprised of convertible notes and warrants, will support Alpha Cognition as they continue the commercialization of their novel therapies for neurodegenerative disorders, including Alzheimer’s disease.   The financing was led by The Benchmark Company, LLC., with their Kestrel Merchant Partners group responsible for sourcing and executing the transaction. Proceeds from the offering will be directed toward payer pricing, contracting work, and manufacturing efforts for Alpha Cognition’s recently approved drug, ZUNVEYL™.   This marks an important milestone in Alpha Cognition’s journey as they advance treatments that address critical unmet needs in the neurodegenerative disease space. We extend our sincere appreciation to Alpha Cognition’s management team for their partnership and collaboration.   As the biopharmaceutical market continues to evolve, Spartan Capital is dedicated to supporting companies poised for innovation and long-term success.   https://lnkd.in/enDJPEDh   #AlphaCognition #BridgeFinancing #NeurodegenerativeDisorders #ZUNVEYL #SpartanCapitalSecurities #InvestmentBanking #ConvertibleNotes #Warrants #Growth #Biopharma #CapitalMarkets #Partnerships #SuccessStory #HealthcareInnovation

Spartan Capital Securities, LLC Serves as Selling Group Member in Alpha Cognition, Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing   We are proud to announce that Spartan Capital Securities LLC participated as a selling group member in Alpha Cognition Inc.'s successful $4.454 million bridge financing. This financing, comprised of convertible notes and warrants, will support Alpha Cognition as they continue the commercialization of their novel therapies for neurodegenerative disorders, including Alzheimer’s disease.   The financing was led by The Benchmark Company, LLC., with their Kestrel Merchant Partners group responsible for sourcing and executing the transaction. Proceeds from the offering will be directed toward payer pricing, contracting work, and manufacturing efforts for Alpha Cognition’s recently approved drug, ZUNVEYL™.   This marks an important milestone in Alpha Cognition’s journey as they advance treatments that address critical unmet needs in the neurodegenerative disease space. We extend our sincere appreciation to Alpha Cognition’s management team for their partnership and collaboration.   As the biopharmaceutical market continues to evolve, Spartan Capital is dedicated to supporting companies poised for innovation and long-term success.   https://lnkd.in/eWpTgsG7   #AlphaCognition #BridgeFinancing #NeurodegenerativeDisorders #ZUNVEYL #SpartanCapitalSecurities #InvestmentBanking #ConvertibleNotes #Warrants #Growth #Biopharma #CapitalMarkets #Partnerships #SuccessStory #HealthcareInnovation

Exclusive: Bain Capital has put together its fourth life sciences fund, with about $3 billion in commitments, as its portfolio rides a wave of recent M&A exits. The fund comes in about $1.1 billion larger than the third rodeo in 2021, and it rivals in size to Flagship's most recent capital haul and the 13th pool that ARCH Venture Partners is currently raising. Bain has backed some of this year's megarounds, including Avistone Biotechnology and Cardurion Pharmaceuticals, and one of its companies, cell therapy maker Kyverna, went public in February. The Boston-based firm has placed bets across many therapeutic areas in its eight-year history. Obesity is its latest foray, with the recently unveiled $400 million venture with Atlas and RTW. More below in Endpoints News: #baincapital #lifesciences #privateequity #venturecapital #biotech #drugdevelopment #biotechstartups

venBio Closes $528 Million Life Sciences Fund V Learn more & get our take 👇 https://lnkd.in/ghUkQKsh “With a highly concentrated portfolio and active involvement in each company, we are proud to have helped build companies that have achieved nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data.” — Dr. Aaron Royston, M.D., Managing Partner at venBio “Our portfolio is directly impacting patient lives, and we could not have achieved this without the ongoing commitment from our limited partners. Fund V is structured to enable us to continue our proven approach of being highly selective in company building, while doubling down on winners around key inflection points, including in crossover rounds and at IPO.” — Dr. Corey Goodman, Managing Partner at venBio “In structuring Fund V, our primary goal was to maintain consistency in our strategy, core team and investment discipline, and we look forward to her continued contributions to the firm.” — Dr. Richard Gaster, M.D., Ph.D., Managing Partner at venBio #funding #lifesciences #SoHCNews

The biotech IPO market continues its steady climb back and the nine IPOs in 2024 now match 2022's total. This was a topic of much discussion at #BIO2024 San Diego and earlier this year at BIO-IT World, where I led an insightful panel discussion on strategies for biotech success, focusing on raising capital from CEOs and VCs. This week, l’ll dive deeper into these topics in a special episode of Biotech2050. Stay tuned for more!

After a challenging 2023, the biotech IPO market has seen a resurgence in early 2024 with several companies, including Alto Neuroscience, ArriVent Biopharma, and Contineum Therapeutics, successfully going public. This positive trend is essential for the industry, providing crucial funding to advance innovative therapies. However, experts caution that it remains to be seen whether this surge will continue throughout the year. The market's long-term performance will depend on broader economic conditions and investor sentiment. Read more in BioPharma Dive: https://ow.ly/I70G50Sa304 At Clora, we’re excited about these developments. Our platform is here to support emerging biotechs by connecting them with flexible, top-tier talent, ensuring they have the expertise needed to easily navigate this dynamic landscape while keeping fixed costs low. #Clora #biotech #IPO #innovation #biopharma

Funding & IPO Trending Upwards for Biotech? If VCs see the public markets bouncing back for biotech this will bolster their Exit possibilities and thus increase appetite to invest in a broader range of companies! As the market shows signs of life, this could lead to a fresh round of funding opportunities for both emerging and established biotech companies. So let's hope any company going public in the biotech world does very well!! Reference: The recent biotech IPOs of Bicara Therapeutics, Zenas BioPharma, and MBX Biosciences, Inc. Biosciences raised a combined total of $703 million. This wave of public offerings is being seen as a sign that investors are regaining confidence in the biotech market after a prolonged period of hesitation. All three companies reported first-day stock gains, with MBX Biosciences seeing a nearly 50% increase. #BiotechIPO #Funding #VentureCapital #PublicMarkets #BiotechInvestment